Shah, Hiral Anil http://orcid.org/0000-0003-0204-451X
Meiwald, Anne
Perera, Chamath
Casabona, Giacomo
Richmond, Peter
Jamet, Nicolas
Funding for this research was provided by:
GlaxoSmithKline Biologicals SA
Article History
Received: 2 October 2023
Accepted: 24 November 2023
First Online: 19 December 2023
Declarations
:
: Giacomo Casabona, Hiral Anil Shah and Nicolas Jamet are employed by GSK. Giacomo Casabona and Hiral Anil Shah holds shares in GSK. Anne Meiwald and Chamath Perera are employed by Adelphi Values PROVE and received funding from GSK to complete the work disclosed in this manuscript. Adelphi Values PROVE has received other consultancy fees from other pharmaceutical companies for unrelated work. PR declared research grants and participation on advisory boards from GSK and Merck, consulting fees, and payment for lectures to his institution and support for attending meetings from GSK, outside of the submitted work. The authors declare no other financial and non-financial relationships and activities.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Due to this reason an ethics committee approval was not required. The authors confirm that this study was performed in accordance with the ethical standards of the Declaration of Helsinki 1964 and its amendments.